Here are the 10-Q quarterly reports from Bowen Acquisition Corp (BOWN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BOWN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOWN filings page.
Bowen Acquisition Corp (BOWN) reported net income of $1,069,485 for the six months ended June 30, 2026, versus a net loss of $1,289,691 a year earlier. The result included a $1,096,351 gain on settlement of its forward purchase agreement and $127,281 of trust-account interest; operating costs were $118,653. The company had no operating revenue.
At June 30, cash was $4,093, the working-capital deficit was $1,428,255, and the trust account held $2,190,570. Management said substantial doubt about the company’s ability to continue as a going concern remained, despite pursuing its Qianzhi business combination and an approved extension of the deadline to December 31, 2026. The business combination remained pending required regulatory approvals. Disclosure controls were ineffective due to a material weakness tied to the lack of a qualified SEC reporting professional.
Nasdaq delisting of the units, ordinary shares, and rights became effective July 20, 2026. After June redemptions, 188,742 public shares remained as of June 30.
Bowen Acquisition Corp reported a $20,822 net loss for the three months ended March 31, 2026, compared with a $2,039,997 net loss a year earlier. At quarter-end it had $6,996 in cash and cash equivalents, $7,741,246 in its trust account, and a $2,458,756 working capital deficit. Management said these conditions raise substantial doubt about its ability to continue as a going concern and concluded its plans do not alleviate that doubt. It intends to pursue the Qianzhi business combination and fund shortfalls through extension loans and other financing arrangements.
The proposed combination with Shenzhen Qianzhi BioTechnology Co. Ltd. remained pending required regulatory approvals, and shareholders approved extending the combination deadline to as late as December 31, 2026. Bowen also reported ineffective disclosure controls as of March 31, 2026, due to a material weakness related to the lack of a qualified SEC reporting professional. The delisting from Nasdaq became effective at the opening of trading on July 20, 2026.
Bowen Acquisition Corp reported a Q3 2025 net loss of $393,970, driven by formation and operating costs and a loss on its forward purchase agreement liability, partly offset by interest income from its trust account. For the first nine months of 2025, the company recorded a net loss of $1.68 million, compared with net income of $2.43 million in the prior-year period, mainly due to the new FPA liability and financing expense.
After heavy shareholder redemptions, cash in the trust account fell to $8.22 million with only 727,871 public shares subject to redemption as of September 30, 2025, down from 6.9 million at year-end 2024. Cash outside the trust was just $17,731, and the company reported a working capital deficit of $2.42 million, leading management to state there is substantial doubt about its ability to continue as a going concern. A pending business combination with Qianzhi remains unconsummated, and Nasdaq has decided to delist the company’s securities after it failed to close the deal by an October 15, 2025 deadline.